These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36632008)
1. Alternative technique for the injection of fluocinolone acetonide (FAc) intravitreal implant (Iluvien Diago T; Fau SG; Roca JM Eur J Ophthalmol; 2023 May; 33(3):1501-1505. PubMed ID: 36632008 [TBL] [Abstract][Full Text] [Related]
2. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472 [TBL] [Abstract][Full Text] [Related]
3. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Holden SE; Kapik B; Beiderbeck AB; Currie CJ Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759 [No Abstract] [Full Text] [Related]
4. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Currie CJ; Holden SE; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150 [TBL] [Abstract][Full Text] [Related]
5. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study. Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010 [TBL] [Abstract][Full Text] [Related]
6. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Currie CJ; Holden SE; Berni E; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143 [TBL] [Abstract][Full Text] [Related]
8. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F; Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results. Elbarky AM Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902 [TBL] [Abstract][Full Text] [Related]
10. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data. Avogaro F; Florido A; Calandri A; Toja F; Vingolo EM Eur Rev Med Pharmacol Sci; 2023 Mar; 27(5):1759-1766. PubMed ID: 36930491 [TBL] [Abstract][Full Text] [Related]
13. Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve. Kessler LJ; Auffarth GU; Khoramnia R J Ocul Pharmacol Ther; 2023 Sep; 39(7):449-455. PubMed ID: 37384926 [No Abstract] [Full Text] [Related]
14. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months. Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW; Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482 [TBL] [Abstract][Full Text] [Related]
15. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262 [TBL] [Abstract][Full Text] [Related]
16. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051 [TBL] [Abstract][Full Text] [Related]
18. [Comparison of available clinical and imaging tools to assess good positioning of a fluocinolone acetonide implant (Iluvien®) in the vitreous cavity after injection]. Jomaa E; Koudsié S; Gontier B; Rougier MB; Gattoussi S; Seguy PH; Azar M; Korobelnik JF; Delyfer MN J Fr Ophtalmol; 2023 Apr; 46(4):369-376. PubMed ID: 36740463 [TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results. Dobler E; Mohammed BR; Chavan R; Lip PL; Mitra A; Mushtaq B Eye (Lond); 2023 Aug; 37(11):2310-2315. PubMed ID: 36513858 [TBL] [Abstract][Full Text] [Related]